• Efficacy and Safety of Besifovir Dipivoxil Maleate in a Phase 3 Trial of Patients With Chronic HBV Infection

Efficacy and Safety of Besifovir Dipivoxil Maleate in a Phase 3 Trial of Patients With Chronic HBV Infection

The efficacy of 48 weeks treatment with besifovir dipivoxil maleate (BSV) for chronic hepatitis B virus (HBV) infection is comparable to that of tenofovir disoproxil fumarate (TDF), with durable effects for 96 weeks, researchers report in the August issue of Clinical Gastroenterology and Hepatology. BSV has a better safety profile

Read more
  • Why Are Patients Cured of HCV Infection Still at Risk for Liver Cancer?

Why Are Patients Cured of HCV Infection Still at Risk for Liver Cancer?

Chronic infection with the hepatitis C virus (HCV) causes epigenetic changes in liver cells that alter gene expression patterns and continue to affect risk for hepatocellular carcinoma (HCC), regardless of patients’ response to direct-activating antiviral (DAA) agents, researchers report in the June issue of Gastroenterology. These alterations might be targeted

Read more
  • Is it Cost Effective to Transplant HCV-positive Livers Into HCV-negative Patients?

Is it Cost Effective to Transplant HCV-positive Livers Into HCV-negative Patients?

A Markov-based mathematical model estimates that transplanting hepatitis C virus (HCV)-positive livers into HCV-negative patients who have received direct-acting antiviral (DAA) agents would be cost effective and improve outcomes, researchers report in the March issue of Clinical Gastroenterology and Hepatology. There has been a steady increase in the number of

Read more
  • Has MELD-Na Improved Outcomes of Patients on the Liver Transplant Waitlist?

Has MELD-Na Improved Outcomes of Patients on the Liver Transplant Waitlist?

Liver allocation based on model for end-stage liver disease-sodium (MELD-Na) score improved waitlist outcomes and provided significant benefit to patients with hyponatremia, researchers report in the November issue of Gastroenterology. However, there are discrepancies in transplantation survival benefit, so current rules for liver allocation might require revision, the authors state. The

Read more
  • Should We Screen for HCC?

Should We Screen for HCC?

Screening patients with cirrhosis for hepatocellular carcinoma (HCC) by abdominal ultrasonography (USS) and/or measurement of serum level of alpha-fetoprotein (AFP) is not associated with reduced mortality from this cancer, reseachers report from a matched case–control study in the October issue of Gastroenterology. Patients with cirrhosis have a high risk (1%–8%

Read more
  • What are the Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis?

What are the Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis?

Vitamin K antagonists (VKAs) increase risk of minor bleeding in patients with cirrhosis given anticoagulants for portal vein thrombosis (PVT), compared to patients without cirrhosis given VKAs, researchers report in the July issue of Clinical Gastroenterology and Hepatology. However, this risk is offset by the ability of VKA to increase portal

Read more
  • Which Patients Are at Greatest Risk From Mushroom Poisoning?

Which Patients Are at Greatest Risk From Mushroom Poisoning?

Almost 20% of patients with liver damage from mushroom (Amanita) poisoning and peak levels of total bilirubin greater than 2 mg/dL require liver transplantation or die, researchers report in the May issue of Clinical Gastroenterology and Hepatology. The authors show that peak level of aspartate aminotransferase (AST) below 4000 IU/L identifies

Read more
  • What are the Effects of Prednisolone in Patients With Severe Alcoholic Liver Disease?

What are the Effects of Prednisolone in Patients With Severe Alcoholic Liver Disease?

Infections are frequent in patients with severe alcoholic liver disease, but are only independently associated with mortality when patients receive prednisolone, researchers report in the April issue of Gastroenterology. This could offset prednisolone’s therapeutic benefit. This study’s senior author, Mark Thursz, discusses the findings in a video abstract. As with

Read more
  • Can Disruption of the Intestinal Epithelial Barrier Contribute to Steatohepatitis?

Can Disruption of the Intestinal Epithelial Barrier Contribute to Steatohepatitis?

Mice with defects in intestinal epithelial permeability develop more severe steatohepatitis when placed on a diet high in saturated fat, fructose, and cholesterol (HFCD) than control mice, and colon tissues from patients with non-alcoholic fatty liver disease (NAFLD) have similar defects in intestinal epithelial permeability, researchers report in the October

Read more
  • Medicaid Denies Almost 50% of Prescriptions for Hepatitis C Drugs in 4 States

Medicaid Denies Almost 50% of Prescriptions for Hepatitis C Drugs in 4 States

Medicaid programs in Delaware, Maryland, New Jersey, and Pennsylvania denied nearly half of all claims in the past year for direct-acting antiviral (DAA) hepatitis C drugs, according to an analysis of pharmacy data presented at the American Association for the Study of Liver Diseases 2015 Liver Meeting. The finding confirms

Read more